Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer,Cancer

当前位置： X-MOL 学术 › Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer
Cancer ( IF 6.1 ) Pub Date : 2021-09-13 , DOI: 10.1002/cncr.33911
Peter S Kirk ₁ , Kehao Zhu ₂ , Yingye Zheng ₂ , Lisa F Newcomb _{1,

3} , Jeannette M Schenk ₃ , James D Brooks ₄ , Peter R Carroll ₅ , Atreya Dash ₆ , William J Ellis ₁ , Christopher P Filson ₇ , Martin E Gleave ₈ , Michael Liss ₉ , Frances Martin ₁₀ , Jesse K McKenney ₁₁ , Todd M Morgan ₁₂ , Peter S Nelson ₁₃ , Ian M Thompson ₁₄ , Andrew A Wagner ₁₅ , Daniel W Lin _{1,

3} , John L Gore ₁

Affiliation

Department of Urology, University of Washington, Seattle, Washington.
Biostatistics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Cancer Prevention Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Department of Urology, Stanford University, Stanford, California.
Department of Urology, University of California, San Francisco, California.
VA Puget Sound Health Care Systems, Seattle, Washington.
Department of Urology, Emory University, Atlanta, Georgia.
Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Department of Urology, University of Texas Health Sciences Center, San Antonio, Texas.
Department of Urology, Eastern Virginia Medical School, Virginia Beach, Virginia.
Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio.
Department of Urology, University of Michigan, Ann Arbor, Michigan.
Division of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
CHRISTUS Medical Center Hospital, San Antonio, Texas.
Division of Urology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Maintaining men on active surveillance for prostate cancer can be challenging. Although most men who eventually undergo treatment have experienced clinical progression, a smaller subset elects treatment in the absence of disease reclassification. This study sought to understand factors associated with treatment in a large, contemporary, prospective cohort.

中文翻译：